Clear Focus on Anti-Infective Cures
AiCuris (name derived from 'anti-infective cures') is a pharmaceutical company focused on the discovery, research and development of novel antiviral and antibacterial agents for the treatment of severe and potentially life-threatening infectious diseases. AiCuris has its roots in Bayer's long history of successful anti-infective drugs. Spun out in 2006 AiCuris owns a broad portfolio of R&D programms, compounds and intellectual property which have been transferred. It´s experienced management team is headed by Prof. Dr. Helga Rübsamen-Schaeff, Bayer´s former Senior Vice President and Head of Anti-Infective Research, in the position of the CEO. Majority investors are Drs. Strüngmann, the founders and previous owners of Hexal. Bayer keeps a minority share in AiCuris.
With its
-
broad and 100 % innovative pipeline from one of the leading pharmaceutical companies in the field of anti-infectives
-
concentration on specialist markets with high medical need
-
team of internationally highly recognized scientists with the knowhow of major pharmaceutical companies
-
and the support by its majority investors, the Drs. Strüngmann,
AiCuris is primed to prosper and to bring innovative drugs to the market for patients with severe, life-threatening infections.
